Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

At least one published study reports a prevalence of the disfiguring movement disorder called Tardive Dyskinesia in patients who have taken the acid reflux medication Reglan (metoclopramide) for at least three months to be as high as 20 percent, according to the drug’s updated safety label. Earlier this year, the Food and Drug Administration issued a black box warning on Reglan (metoclopramide) and ordered the drug’s label be updated to include the risk of Tardive Dyskinesia after receiving numerous reports of the condition in patients who had taken the drug.

Read the rest of this entry »